Skip to content

Medical emergency? What to do

HRT ups breast cancer risk across racial groups

3-RXPublished September 20, 20053 min read

Key points

  • The use of estrogen-progestin hormonal therapy increases the risk of breast cancer among postmenopausal women regardless of racial differences, according to results of a study of more than 55,000 American women of different racial and ethnic backgrounds reported in the International Journal of Cancer September 16th.
  • Most previous studies that have shown a link between menopausal hormone therapy and increased breast cancer risk have been conducted in white women and few have considered prognostic factors such as weight (body mass index).
  • Current users of estrogen-progestin therapy had a 29 percent higher risk of developing breast cancer after 5 years of treatment, while users of estrogen-only therapy had only a 10 percent increased risk.
  • The data also hint that the risk of breast cancer for estrogen-progestin users is somewhat higher for lean women -- those with a body mass index below 25 -- compared with heavier women.

The use of estrogen-progestin hormonal therapy increases the risk of breast cancer among postmenopausal women regardless of racial differences, according to results of a study of more than 55,000 American women of different racial and ethnic backgrounds reported in the International Journal of Cancer September 16th.

"The most important finding in this paper," said Dr. Malcolm Pike of the University of Southern California in Los Angeles, "is that the increased risk of breast cancer from menopausal estrogen/progestin replacement therapy is found in all ethnic groups we studied -- African Americans, Hawaiians, Japanese Americans and Latinas (mainly Mexican-Americans) as well as in whites."

"The result in whites confirms earlier reports," he noted.

Millions of women have relied on hormone replacement therapy for many years, but recent research has suggested that the benefits of the treatment -- alleviating hot flashes, mood swings and other bothersome symptoms of the menopause and preventing osteoporosis -- may be outweighed by its risks, specifically, breast cancer, heart attack and strokes.

Most previous studies that have shown a link between menopausal hormone therapy and increased breast cancer risk have been conducted in white women and few have considered prognostic factors such as weight (body mass index). The current study provides some of the first results comparing breast cancer risk among different racial and ethnic groups in relation to hormone therapy use.

Among the 55,000+ women in the study, 1615 cases of breast cancer were diagnosed over an average of 7.3 years.

Current users of estrogen-progestin therapy had a 29 percent higher risk of developing breast cancer after 5 years of treatment, while users of estrogen-only therapy had only a 10 percent increased risk.

The increase in breast cancer risk with combined estrogen-progestin therapy was seen in all five ethnic groups and the increase with estrogen-only therapy was seen in four of the five groups.

The data also hint that the risk of breast cancer for estrogen-progestin users is somewhat higher for lean women -- those with a body mass index below 25 -- compared with heavier women. The authors emphasize, however, "data on this aspect of the relationship between hormone therapy use and risk are scarce and it is too early to draw a firm conclusion."

They also note there was "still a clear increase in risk in heavier women."

Summing up, Pike noted that "menopausal estrogen-alone therapy is much safer as regards breast cancer, but can only be used for a short time without increasing a woman's risk of endometrial cancer."

"A proposed solution to this dilemma," he offered, "is to still add some progestin to the estrogen replacement therapy but to add it much less frequently than monthly or to use an intrauterine device that contains a progestin, but that effectively provides progestin only to the uterus."

SOURCE: International Journal of Cancer September 16, 2005.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underBreast Cancer
Cancer

Strong social ties benefit breast cancer patients

Breast cancer patients who have a strong social support system in the first year after diagnosis are less likely to die or have a recurrence of cancer, according to new research from Vanderbilt-Ingram Cancer Center…

3 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.